What the company does
Orientbio breeds and supplies laboratory animals, purpose-raised mice, rats, and other species used in drug safety and efficacy testing, along with related research services such as pharmacokinetic studies and preclinical contract research.
Its customers are pharmaceutical companies, biotech firms, and research institutions that need certified animal models before advancing a drug candidate to human trials. The company is listed on KOSPI, South Korea's main stock exchange, and operates facilities designed to keep animals free from external contamination, meeting the good laboratory practice standards required for regulatory submissions.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$20.9M
- FY2024US$20.3M
- FY2025US$21.3M
Operating profit
- FY2023US$1.1M
- FY2024−US$468.1K
- FY2025−US$2.2M
Net income
- FY2023−US$9M
- FY2024US$9.3M
- FY2025−US$9.6M
Key ratios (FY2025)
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?